0001209191-22-024859.txt : 20220419
0001209191-22-024859.hdr.sgml : 20220419
20220419195948
ACCESSION NUMBER: 0001209191-22-024859
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220418
FILED AS OF DATE: 20220419
DATE AS OF CHANGE: 20220419
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Detheux Michel
CENTRAL INDEX KEY: 0001816196
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 22836072
MAIL ADDRESS:
STREET 1: C/O ITEOS THERAPEUTICS, INC.
STREET 2: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: iTeos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001808865
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 ARSENAL STREET
STREET 2: BLDG 312, FLOOR 3, SUITE 301
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 857-204-4583
MAIL ADDRESS:
STREET 1: 321 ARSENAL STREET
STREET 2: BLDG 312, FLOOR 3, SUITE 301
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-04-18
0
0001808865
iTeos Therapeutics, Inc.
ITOS
0001816196
Detheux Michel
321 ARSENAL STREET
WATERTOWN
MA
02472
0
1
0
0
Chief Executive Officer
Common Stock
2022-04-18
4
M
0
11500
4.23
A
37763
D
Common Stock
2022-04-18
4
S
0
11467
31.87
D
26296
D
Common Stock
2022-04-18
4
S
0
33
32.64
D
26263
D
Stock Option (Right to Buy)
4.23
2022-04-18
4
M
0
11500
0.00
D
2030-05-01
Common Stock
11500
144464
D
Stock Option (Right to Buy)
4.23
2030-05-01
Common Stock
185000
185000
I
By MG3A
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.39 to $32.37, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
25% of the shares subject to the stock option vested on May 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date.
/s/ Adi Osovsky, as Attorney-in-Fact
2022-04-19